European Commission grants rezafungin orphan drug status for the treatment of invasive candidiasis

Rezafungin is a once-weekly echinocandin – a class of antifungals that inhibit β (1, 3)-D- glucan synthase, an enzyme which plays a key role in the integrity of the fungal cell wall. It is currently being compared to caspofungin in Phase III trials.

PharmaTimes